|
| Status |
Public on Jan 16, 2014 |
| Title |
SUM44 3hr E2 B |
| Sample type |
RNA |
| |
|
| Source name |
Hormone deprived SUM44 cells in culture following treatment
|
| Organism |
Homo sapiens |
| Characteristics |
tissue: Cell culture
source: Asterand
cell line: SUM44
treatment: E2
time: 3hr
|
| Treatment protocol |
Following deprivation, cells were treated for 3 or 24 hours with 1nM E2 or vehicle (0.01% EtOH).
|
| Growth protocol |
Cells were hormone deprived by replacing growth medium with IMEM+10% charcoal stripped serum for 3 days.
|
| Extracted molecule |
total RNA |
| Extraction protocol |
Following treatment, cells were lysed and RNA was harvested using the Illustra RNAspin Mini kit (GE Health)
|
| Label |
biotin
|
| Label protocol |
cRNA synthesis and labeling was performed using the Ambion MessageAmp Premier Kit (Life Technologies).
|
| |
|
| Hybridization protocol |
cRNA was hybridized to U133A 2.0 arrays (Affymetrix, Santa Clara, CA).
|
| Scan protocol |
cRNA synthesis and labeling, hybridization, and scanning were performed by the University of Pittsburgh Cancer Biomarkers Facility.
|
| Description |
Gene expression data from hormone deprived SUM44 breast cancer cells following 3hr treatment with 1nM estradiol
|
| Data processing |
The data is RMA normalized using 'affy' package in R-Bioconductor
|
| |
|
| Submission date |
Sep 09, 2013 |
| Last update date |
Jan 17, 2014 |
| Contact name |
Uma Chandran |
| E-mail(s) |
chandran@pitt.edu
|
| Phone |
412-648-9326
|
| Organization name |
University of Pittsburgh
|
| Department |
BioMedical Informatics
|
| Street address |
5150 Center Ave
|
| City |
Pittsburgh |
| State/province |
PA |
| ZIP/Postal code |
15232 |
| Country |
USA |
| |
|
| Platform ID |
GPL571 |
| Series (2) |
| GSE50694 |
Endocrine response in invasive lobular carcinoma is characterized by unique estrogen-mediated gene expression and de novo tamoxifen resistance (SUM44) |
| GSE50695 |
Endocrine response in invasive lobular carcinoma is characterized by unique estrogen-mediated gene expression and de novo tamoxifen resistance |
|
